Abbott receives CE mark for next generation CL disinfection solution

Article

A new disinfecting technology for soft contact lenses from Abbott has received European regulatory approval. Complete RevitaLens Multipurpose Disinfecting Solution was developed in partnership with the Holden Vision Institute.

A new disinfecting technology for soft contact lenses from Abbott has received European regulatory approval. Complete RevitaLens Multipurpose Disinfecting Solution was developed in partnership with the Holden Vision Institute, which also helped to develop Silicone Hydrogel lenses.

“This advanced, next-generation solution establishes a new standard of disinfecting technology for contact lens wearers,” said Jim Mazzo, senior vice president, Abbott Medical Optics. “ Proper contact lens care, including a rub and rinse regimen using Complete RevitaLens Multipurpose Disinfecting Solution, will help patients achieve clean and comfortable lenses, extended wear times, and overall enhanced lens- wearing satisfaction. ”

Abbott plans to begin shipment of Complete RevitaLens Multipurpose Disinfecting Solution in select European markets this June with a full commercial launch in Europe by year end.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.